The November 2017 issue of Pharmafocus is now live!
pharmafile | October 23, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | CAR-T, EMA, NHS, Pharmafocus, Trump, brexit, clinical trial transparency, pharma
The November edition of Pharmafocus is now live and available to read online here!
As the United States flounders in the midst of its devastating opioid crisis, the latest moves to tackle the issue have fallen prey to controversy as President Trump’s nomination for US Drug Czar withdrew from the running after just two days over his alleged involvement in the escalation of the dilemma. You can get up to speed with the full details of the story in our front page feature.
Stemming from details reported in a study from King’s College London (KCL) and the London School of Economics (LSE), the EMA was recently hit by the stinging accusation that 57% of the cancer drugs it approved show no clinical benefit in reality. We spoke to LSE’s Dr Huseyin Naci to get a clear picture of how impactful these findings are – before the EMA spoke out against the allegations itself. This month’s EU News has both sides of the story.
In the UK it’s a similarly shocking picture as a wave of fresh reports indicate that not only is the NHS’ ability to perform its duties ever-waning as healthcare challenges mount and funding is stripped away, but the possibility of a ‘hard Brexit’ could deal another immense economic blow to the service. You can find the full stories in this month’s UK News.
In just over a month, the world saw the first-ever approvals of CAR-T therapies in the US for the treatment of cancer in developments that were heralded as “historic”. As part of one of our monthly in-depth features, we delve into the ground-breaking technology to discover how it works, how it is bringing treatment options to patients previously had none, and the challenges it faces in achieving wider adoption.
Related Content
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …
